Drug profile · INN
cangrelor
KENGREXAL
cangrelor (KENGREXAL) is a purinergic receptor p2y12 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — cangrelor
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
cangrelor (KENGREXAL) is a purinergic receptor p2y12 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Purinergic receptor P2Y12 antagonist
Primary target: P2Y purinoceptor 12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is cangrelor?
cangrelor (KENGREXAL) is a purinergic receptor p2y12 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for cangrelor?
KENGREXAL is a marketed brand name for cangrelor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cangrelor?
cangrelor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.